title: Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA.
abstract: Transcriptional silencing of the gene encoding the fragile X mental retardation protein (FMRP) causes fragile X syndrome (FXS). FMRP acts as a translational repressor at central synapses, and molecular and synaptic plasticity studies have shown that the absence of this protein alters metabotropic glutamate 5 receptors (mGlu5Rs)-mediated signaling. In the striatum of mice lacking FMRP, we found enhanced activity of diacylglycerol lipase (DAGL), the enzyme limiting 2-arachidonoylglicerol (2-AG) synthesis, associated with altered sensitivity of GABA synapses to the mobilization of this endocannabinoid by mGlu5R stimulation with DHPG. Mice lacking another repressor of synaptic protein synthesis, BC1 RNA, also showed potentiated mGlu5R-driven 2-AG responses, indicating that both FMRP and BC1 RNA act as physiological constraints of mGlu5R/endocannabinoid coupling at central synapses. The effects of FMRP ablation on DAGL activity and on DHPG-mediated inhibition of GABA synapses were enhanced by simultaneous genetic inactivation of FMRP and BC1 RNA. In double FMRP and BC1 RNA lacking mice, striatal levels of 2-AG were also enhanced compared with control animals and to single mutants. Our data indicate for the first time that mGlu5R-driven endocannabinoid signaling in the striatum is under the control of both FMRP and BC1 RNA. The abnormal mGlu5R/2-AG coupling found in FMRP-KO mice emphasizes the involvement of mGlu5Rs in the synaptic defects of FXS, and identifies the modulation of the endocannabinoid system as a novel target for the treatment of this severe neuropsychiatric disorder.
authors.affiliation: Dipartimento di Scienze Biomediche, Università degli Studi di Teramo, Teramo, Italy. mmaccarrone@unite.it
authors.forename: Mauro
authors.initials: M
authors.lastname: Maccarrone
authors.forename: Silvia
authors.initials: S
authors.lastname: Rossi
authors.forename: Monica
authors.initials: M
authors.lastname: Bari
authors.forename: Valentina
authors.initials: V
authors.lastname: De Chiara
authors.forename: Cinzia
authors.initials: C
authors.lastname: Rapino
authors.forename: Alessandra
authors.initials: A
authors.lastname: Musella
authors.forename: Giorgio
authors.initials: G
authors.lastname: Bernardi
authors.forename: Claudia
authors.initials: C
authors.lastname: Bagni
authors.forename: Diego
authors.initials: D
authors.lastname: Centonze
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D013759:Dronabinol / Q000031:analogs & derivatives / Q000494:pharmacology; D063388:Endocannabinoids; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics*; D005786:Gene Expression Regulation / Q000235:genetics*; D005989:Glycerides / Q000378:metabolism; D066298:In Vitro Techniques; D053444:Inhibitory Postsynaptic Potentials / Q000187:drug effects / Q000235:genetics; D008071:Lipoprotein Lipase / Q000378:metabolism; D008564:Membrane Potentials / Q000187:drug effects / Q000235:genetics; D008734:Methoxyhydroxyphenylglycol / Q000031:analogs & derivatives / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D018408:Patch-Clamp Techniques / Q000379:methods; D010880:Piperidines / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects / Q000235:genetics; D011720:Pyrazoles / Q000494:pharmacology; D020733:RNA, Small Cytoplasmic / Q000235:genetics*; D018092:Kainic Acid Receptors / Q000378:metabolism*; D018709:Statistics, Nonparametric
chemical_list: D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D013759:Dronabinol; D063388:Endocannabinoids; D018691:Excitatory Amino Acid Antagonists; D051860:Fragile X Messenger Ribonucleoprotein 1; D005989:Glycerides; D008071:Lipoprotein Lipase; D008734:Methoxyhydroxyphenylglycol; D010880:Piperidines; D011720:Pyrazoles; D020733:RNA, Small Cytoplasmic; D018092:Kainic Acid Receptors; C117734:BC1 RNA; C497684:Fmr1 protein, mouse; C103505:AM 251; C094503:glyceryl 2-arachidonate; C062018:HU 211; C010117:3,4-dihydroxyphenylglycol
references.citation: Proc Natl Acad Sci U S A. 2002 May 28;99(11):7746-50
references.pmid: 12032354
references.citation: Mol Cell Neurosci. 2007 Jun;35(2):302-10
references.pmid: 17434747
references.citation: J Neurosci. 2006 Jul 5;26(27):7143-6
references.pmid: 16822969
references.citation: J Cell Biol. 2003 Nov 10;163(3):463-8
references.pmid: 14610053
references.citation: Neuron. 2007 Dec 20;56(6):955-62
references.pmid: 18093519
references.citation: J Neurosci. 2007 Aug 15;27(33):8885-92
references.pmid: 17699670
references.citation: Trends Neurosci. 2007 May;30(5):228-35
references.pmid: 17408758
references.citation: Neuron. 2008 Oct 23;60(2):201-14
references.pmid: 18957214
references.citation: J Physiol. 2008 Mar 15;586(6):1503-8
references.pmid: 18202092
references.citation: J Neurosci. 2007 Jan 17;27(3):496-506
references.pmid: 17234582
references.citation: Biol Psychiatry. 2008 May 15;63(10):963-73
references.pmid: 18028882
references.citation: Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10819-24
references.pmid: 12136125
references.citation: J Dev Behav Pediatr. 2006 Feb;27(1):63-74
references.pmid: 16511373
references.citation: J Neurosci. 2002 Dec 1;22(23):10232-41
references.pmid: 12451124
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3615-20
references.pmid: 14993603
references.citation: J Neurosci. 2009 Aug 12;29(32):9977-86
references.pmid: 19675232
references.citation: Neuropharmacology. 2008 Sep;55(4):392-5
references.pmid: 18602651
references.citation: Mol Pharmacol. 2005 Nov;68(5):1196-202
references.pmid: 16051747
references.citation: Biochim Biophys Acta. 2006 Feb;1761(2):205-12
references.pmid: 16466961
references.citation: J Neurosci. 2004 Oct 20;24(42):9425-33
references.pmid: 15496678
references.citation: Proc Natl Acad Sci U S A. 1997 May 13;94(10):5395-400
references.pmid: 9144248
references.citation: Cell. 2003 Feb 7;112(3):317-27
references.pmid: 12581522
references.citation: J Neurosci. 2008 Jun 18;28(25):6483-92
references.pmid: 18562619
references.citation: Curr Opin Neurobiol. 2006 Jun;16(3):265-9
references.pmid: 16707258
references.citation: Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2454-9
references.pmid: 17287348
references.citation: Trends Neurosci. 2004 Jul;27(7):370-7
references.pmid: 15219735
references.citation: Front Neural Circuits. 2009 Oct 07;3:14
references.pmid: 19838324
references.citation: Mol Cell Neurosci. 2007 Mar;34(3):343-54
references.pmid: 17254795
references.citation: Science. 2000 May 19;288(5469):1254-7
references.pmid: 10818003
references.citation: Cell. 2006 Oct 6;127(1):49-58
references.pmid: 17018276
references.citation: J Neurosci Res. 2005 Jun 1;80(5):646-54
references.pmid: 15880742
references.citation: Cell. 2008 Sep 19;134(6):1042-54
references.pmid: 18805096
references.citation: J Cell Biol. 2005 Dec 5;171(5):811-21
references.pmid: 16330711
references.citation: J Neurochem. 2009 Apr;109(2):371-81
references.pmid: 19187444
references.citation: Eur J Pharmacol. 2000 Nov 17;408(2):161-8
references.pmid: 11080522
references.citation: J Neurosci Res. 2006 May 1;83(6):929-43
references.pmid: 16511857
references.citation: Bioorg Med Chem Lett. 2008 Nov 15;18(22):5838-41
references.pmid: 18657971
references.citation: Trends Pharmacol Sci. 2008 May;29(5):229-33
references.pmid: 18394720
references.citation: Am J Med Genet. 1991 Mar 15;38(4):542-7
references.pmid: 2063895
references.citation: Nat Neurosci. 2008 Feb;11(2):152-9
references.pmid: 18204441
references.citation: Nat Rev Neurosci. 2005 May;6(5):376-87
references.pmid: 15861180